The latest addition to Bedford’s biomedical lineup is a Taipei-based firm that says it aims “to deliver new biologics in hematology and oncology.”
PharmaEssentia is preparing an “innovation research center” in facilities at 36 Crosby Drive, an Anchor Line Partners and Alloy Properties research park known as The Core at Crosby.
Over the next two years, the company hopes to recruit 25 scientists “who have deep knowledge in immunology and interest in developing novel drugs employing disease-driving biology, novel technology in protein engineering, antibody discovery and new modality development.”
The 11,675-square-foot space is being renovated and is expected to be fully operational in the summer as the firm’s U.S. research and development center. The U.S. operational headquarters is in Burlington.
The research center “will be equipped with a state-of-the-art lab featuring cutting-edge technology to support the identification and development of therapeutic opportunities,” the company said in its announcement.
Peter Dominski, director of leasing for the owner, confirmed that PharmaEssentia will be moving into space “customized to meet the needs of their growing operations. We couldn’t be more excited to host such an innovative and dynamic company.”
PharmaEssentia was founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies. Its current focus includes development of therapy in oncology, hematology, and immunology disease areas.
“This new center will grow PharmaEssentia’s research capabilities and help cultivate local talent, building upon our invention and discovery-based innovation efforts originally established in Taiwan that led to a transformative advancement for polycythemia vera (a rare form of blood cancer),” said Ko-Chung Lin, PhD., founder and chief executive officer, in the statement.
“We are expanding our technical expertise within the epicenter of biotechnology in the U.S., attracting experts to focus on discovery efforts in hematology, oncology, and immunology to better understand and address the critical needs of those living with difficult-to-treat diseases. Data scientists will leverage artificial intelligence and machine learning to inform new target and indication selections.”
The new facility will be led by Lih-Ling Lin, Ph.D., chief scientific officer for PharmaEssentia.